This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Trials of interferon beta-1b

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The first trials of interferon in multiple sclerosis used recombinant interferon beta-1b.

Interferon beta-1b differs from the human cytokine in two ways:

  • has an aminoacid substitution at one position
  • is non-glycosylated

Patients treated with the high dose of 8 MIU subcutanesouly on alternate days had the following significant benefits:

  • 34% reduction in the relapse rate
  • marked reduction in disease burden as assessed by T2-weighted MRI imaging after two years

The trials with interferon beta-1b did not show a significant reduction in accumulated disability.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page